Nos Publications

Retrouvez tous nos travaux de Recherche
2019
  • Vialaret J, Lehmann S, Hirtz C. Intact Protein Analysis by LC-MS for Characterizing Biomarkers in Cerebrospinal Fluid. Methods Mol Biol. 2019;1959:163-172.
  • Bystander effectors of chondrosarcoma cells irradiated at different LET impair proliferation of chondrocytes. Lepleux C, Marie-Brasset A, Temelie M, Boulanger M, Brotin E,  Goldring MB, Hirtz C, Varès G, Nakajima T, Saintigny Y, Savu D, Chevalier F. Journal of Cell Communication and Signaling. https://doi.org/10.1007/s12079-019-00515-9
  • Relaño-Ginés A, Lehmann S, Deville de Périère D, Hirtz C Dental stem cells as a promising source for cell therapies in neurological diseases. Crit Rev Clin Lab Sci. 2019 May;56(3):170-181
  • Peyron PA, Lehmann S, Delaby C, Baccino E, Hirtz C. Biochemical markers of time since death in cerebrospinal fluid: a first step towards “Forensomics”. Crit Rev Clin Lab Sci. (2019) In press (IF 6.481)
  • Paterson RW, Gabelle A, Lucey BP, Barthélemy NR, Leckey CA, Hirtz C, Lehmann S, Sato C, Patterson BW, West T, Yarasheski K, Rohrer JD, Wildburger NC, Schott JM, Karch CM, Wray S, Miller TM, Elbert DL, Zetterberg H, Fox NC, Bateman RJ. SILK studies – capturing the turnover of proteins linked to neurodegenerative diseases. Nat Rev Neurol. 2019 Jul;15(7):419-427.
  • Murall CL, Rahmoun M, Selinger C, Baldellou M, Bernat C, Bonneau M, Boué V, Buisson M, Christophe G, D’Auria G, Taroni F, Foulongne V, Froissart R, Graf C, Grasset S, Groc S, Hirtz C, Jaussent A, Lajoie J, Lorcy F, Picot E, Picot MC, Ravel J, Reynes J, Rousset T, Seddiki A, Teirlinck M, Tribout V, Tuaillon É, Waterboer T, Jacobs N, Bravo IG, Segondy M, Boulle N, Alizon S. Natural history, dynamics, and ecology of human papillomaviruses in genital infections of young women: protocol of the PAPCLEAR cohort study.
  • BMJ Open. 2019 Jun 11;9(6):e025129. doi: 10.1136/bmjopen-2018-025129.
  • Pontier D, Picart C, El Baidouri M, Roudier F, Xu T, Lahmy S, Llauro C, Azevedo J, Laudié M, Attina A, Hirtz C, Carpentier MC, Shen L, Lagrange T. The m6A pathway protects the transcriptome integrity by restricting RNA chimera formation in plants. Life Sci Alliance. 2019 May 29;2(3).
  • Thouvenot E, Demattei C, Lehmann S, Maceski-Maleska A, Hirtz C, Juntas-Morales R, Pageot N, Esselin F, Alphandéry S, Vincent T, Camu W. Serum neurofilament light chain at time of diagnosis is an independent prognostic factor of survival in amyotrophic lateral sclerosis.Eur J Neurol. 2019 Aug 22. doi: 10.1111/ene.14063.
  • Contreras-Aguilar MD, Vialaret J, de Périère DD, Escribano D, Lehmann S, Tecles F, Cerón JJ, Hirtz C.
  • Variation of human salivary alpha-amylase proteoforms in three stimulation models. Clin Oral Investig. 2019 Aug 6. doi: 10.1007/s00784-019-03021-9.
  • Thouvenot E, Demattei C, Lehmann S, Maceski-Maleska A, Hirtz C, Juntas-Morales R, Pageot N, Esselin F, Alphandéry S, Vincent T, Camu W. Serum neurofilament light chain at time of diagnosis is an independent prognostic factor of survival in amyotrophic lateral sclerosis. Eur J Neurol. 2019 Aug 22. doi: 10.1111/ene.14063.
2018
  • Vialaret J, Wessels H, van Gool AJ, Lehmann S, Gabelle A, Wood J, Bern M, Paape R, Suckau D, Kruppa G and C Hirtz. Towards a routine application of Top-Down approaches for Label-Free discovery Workflows. Journal of Proteomics (IF :3.88). 2018 Mar 20;175:12-26.
  • Mertens B, Orti V, Vialaret J, Gibert P, Relaño-Ginés A, Lehmann S, de Périère DD, Hirtz C. Assessing a multiplex-targeted proteomics approach for the clinical diagnosis of periodontitis using saliva samples. Bioanalysis. 2018 Jan;10(1):35-45. doi: 10.4155/bio-2017-0218 (IF:2.7).
  • Dauvilliers Y, Chenini S, Vialaret J, Delaby C, Guiraud L, Gabelle A, Lopez R, Hirtz C, Jaussent I, Lehmann S. Association between serum hepcidin level and restless legs syndrome. Mov Disord. 2018 Feb 8. doi: 10.1002/mds.27287
  • Vialaret J, Picas A, Delaby C, Bros P, Lehmann S, Hirtz C. Nano-flow vs standard-flow: Which is the more suitable LC/MS method for quantifying hepcidin-25 in human serum in routine clinical settings? Journal of Chromatography B. 2018, Vol 1086: 110-117.
  • Orti V, Mertens B, Vialaret J, Gibert P, Relaño-Ginés A, Lehmann S, de Périère DD, Hirtz C Data from a targeted proteomics approach to discover biomarkers in saliva for the clinical diagnosis of periodontitis. Data in Brief. 2018, Vol 18, Pages 294-299
  • Vialaret J, Wessels H, van Gool AJ, Lehmann S, Gabelle A, Wood J, Bern M, Paape R, Suckau D, Kruppa G and C Hirtz. Identification of multiple proteoforms biomarkers on clinical samples by routine Top-Down approaches. Data in Brief. 2018, Vol 18, June 2018, Pages 1013-1021
  • Vialaret J, Kadi S, Tiers L,  O’Flynn R, Lehmann S and Hirtz C, Albumin depletion of human serum to improve quantitative clinical proteomics”. Current Topics in Peptide & Protein Research. 2018 Sous presse
  • Fortea J, Carmona-Iragui M, Benejam B, Fernández S, Videla L, Barroeta I, Alcolea D, Pegueroles J, Muñoz L, Belbin O, de Leon MJ, Maceski AM, Hirtz C, Clarimón J, Videla S, Delaby C, Lehmann S, Blesa R, Lleó A. Plasma and CSF biomarkers for the diagnosis of Alzheimer’s disease in adults with Down syndrome: a cross-sectional study. Lancet Neurol. 2018 : 17(10):860-869
  • Piton M, Hirtz C, Desmetz C, Milhau J, Lajoix AD, Bennys K, Lehmann S, Gabelle A. Alzheimer’s Disease: Advances in Drug Development. J Alzheimers Dis. 2018;65(1):3-13.
  • Vialaret J, Broutin S, Pugnier C, Santelé S, Jaffuel A, Barnes A, Tiers L, Pelletier L, Lehmann S, Paci A, Hirtz C. What sample preparation should be chosen for targeted MS monoclonal antibody quantification in human serum? Bioanalysis. 2018 May 1;10(10):723-735.
  • Incamps A, Saez-Boiteau C, Tiede SL, Rebillard P, Schulte J, Vialaret J, Beinrucker A, Lehmann S, Hirtz C. Impact of biological matrix on inflammatory protein biomarker quantification based on targeted mass spectrometry.Bioanalysis. 2018 Sep 1;10(17):1383-1399.
  • Darlix A, Hirtz C, Thezenas S, Maceski A, Gabelle A, Lopez-Crapez E, De Forges H, Firmin N, Guiu S, Jacot W, Lehmann S. The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases. BMC Cancer. 2019 Jan 30;19(1):110.
  • Molinari N, Roche S, Peoc’h K, Tiers L, Séveno M, Hirtz C, Lehmann S. Sample Pooling and Inflammation Linked to the False Selection of Biomarkers for Neurodegenerative Diseases in Top-Down Proteomics: A Pilot Study. Front Mol Neurosci. 2018 Dec 18;11:477.
2017
  • Maleska A, Hirtz C, Casteleyn E, Villard O, Ducos J, Avignon A, Sultan A, Lehmann S. Comparison of HbA1c detection in whole blood and dried blood spots using an automated ion-exchange HPLC system. Bioanalysis. 2017 Mar;9(5):427-434 (IF:2.7).
  • Lasocki S, Puy H, Mercier G, Lehmann S, Asfar P, Mercat A, Gaillard T, Gergaud S, Lasocki S, Sargentini C, Geneve C, Montravers P, Lefebvre T, Puy H, Mercier G, Nagot N, Delaby C, Hirtz C, Lehmann S, Vialaret J, Chanques G, Jaber S, Asehnoune K, Roquilly A, Dahyot-Fizelier C, Mimoz O, Isslame S, Seguin P, Barbaz M, Ferrandiere M. Impact of iron deficiency diagnosis using hepcidin mass spectrometry dosage methods on hospital stay and costs after a prolonged ICU stay: Study protocol for a multicentre, randomised, single-blinded medico-economic trial. Anaesth Crit Care Pain Med. 2017 Sep 14. pii: S2352-5568(17)30089-9. doi: 10.1016 (IF:1.54)
  • Quijada‐Morin N, Garcia F, Lambert K, Walker A‐S, Tiers L, Viaud M, Sauvage F‐X, Hirtz C and Saucier C. Strain effect on extracellular laccase activities from Botrytis cinereal. Australian Journal of Grape and Wine Research. (2017) doi: 10.1111/ajgw.12322 (IF:2.635)
2016
  • Hirtz C, Vialaret J, Nowak N, Gabelle A, Deville de Périère D and Lehmann S (2016). Absolute quantification of 35 plasma biomarkers in human saliva using targeted mass spectrometry. Bioanalysis. (IF :3.1) Jan;8(1):43-53.
  • Hirtz C, Vialaret J, Gabelle A, Nowak N, Dauvilliers Y and Lehmann S (2016). From radioimmunoassay to mass spectrometry: a new method to quantify orexin-A (hypocretin-1) in cerebrospinal fluid. Scientific Reports. (IF:5.9) . 2016 May 11;6: 25162.
  • Lehmann S, Vialaret J, Delatour V, Bros P, Brede C, Hirtz C and on behalf of the IFCC Working Group  on Clinical Quantitative Mass Spectrometry Proteomics (WG-cMSP) (2016). Mass spectrometry proteomics for medical laboratory: what could be the future? Clin Chem Lab Med. (IF:3) pii: S0009-8981(16)30246-7. doi: 10.1016/j.cca.2016.06.001
  • Hassan D, Provansal M, Lehmann S, Rizk M, Moez P, Vialaret J, Hirtz C, Essa A, Agamia H (2016). Proteomic profile of cerebrospinal fluid in patients with multiple sclerosis using two dimensional gel electrophoresis.Br J Biomed Sci. (IF : 1.3)  2016 Jun 2:1-5
  • Renard D, Gabelle A, Hirtz C, Demattei C, Thouvenot E and Lehmann S (2016). Cerebrospinal fluid Alzheimer’s disease biomarkers in isolated supratentorial cortical superficial siderosis. Journal of Alzheimer Disease. (IF:4.1) 18;54(4):1291-1295.
  • Hirtz C, Vialaret J, Nowak N, Gabelle A, Deville de Périère D and Lehmann S (2016). Absolute quantification of 35 plasma biomarkers in human saliva using targeted mass spectrometry. Bioanalysis. (IF :3.1) Jan;8(1):43-53.
  • Hirtz C, Vialaret J, Gabelle A, Nowak N, Dauvilliers Y and Lehmann S (2016). From radioimmunoassay to mass spectrometry: a new method to quantify orexin-A (hypocretin-1) in cerebrospinal fluid. Scientific Reports. (IF:5.9) . 2016 May 11;6: 25162.
  • Lehmann S, Vialaret J, Delatour V, Bros P, Brede C, Hirtz C and on behalf of the IFCC Working Group  on Clinical Quantitative Mass Spectrometry Proteomics (WG-cMSP) (2016). Mass spectrometry proteomics for medical laboratory: what could be the future? Clin Chem Lab Med. (IF:3) pii: S0009-8981(16)30246-7. doi: 10.1016/j.cca.2016.06.001
  • Hassan D, Provansal M, Lehmann S, Rizk M, Moez P, Vialaret J, Hirtz C, Essa A, Agamia H (2016). Proteomic profile of cerebrospinal fluid in patients with multiple sclerosis using two dimensional gel electrophoresis.Br J Biomed Sci. (IF : 1.3)  2016 Jun 2:1-5
  • Renard D, Gabelle A, Hirtz C, Demattei C, Thouvenot E and Lehmann S (2016). Cerebrospinal fluid Alzheimer’s disease biomarkers in isolated supratentorial cortical superficial siderosis. Journal of Alzheimer Disease. (IF:4.1) 18;54(4):1291-1295.
2015
  • Tall, Lehmann S, Diouf E, Gérard C,  Filali S, Hirtz C, Gabert L, Sauvinet V, Pirot F, Pivot C. (2015) Injectable preparation of labeled leucine with the carbon 13 for a clinical research program on the Alzheimer disease: Pharmaceutical control of raw materials and the finished product and stability study. Ann Pharm Fr. 73(1):43-59. (IF : 0.58)    
  • Tall, Lehmann S, Diouf E, Gérard C,  Filali S, Hirtz C, Gabert L, Sauvinet V, Pirot F, Pivot C. (2015) Injectable preparation of labeled leucine with the carbon 13 for a clinical research program on the Alzheimer disease: Pharmaceutical control of raw materials and the finished product and stability study. Ann Pharm Fr. 73(1):43-59. (IF : 0.58)    
  • Hirtz C, Lehmann S (2015). Blood sampling using “dried blood spot”: a clinical biology revolution underway? Ann Biol Clin (Paris). Feb 1;73(1):25-37. (IF :1.9)            
  • Bros P, Vialaret J, Barthelemy N, Delatour V, Gabelle A, Lehmann S, Hirtz C. (2015) Antibody-free quantification of seven tau peptides in human CSF using targeted mass spectrometry. Front Neurosci. 1;9: 302. (IF :3.7)      
  • Morzel M, Neyraud E, Brignot H, Ducoroy P, Jeannin A, Lucchi G, Truntzer C, Canlet C, Tremblay-Franco M, Hirtz C, Gaillard S, Peretti N, Feron G. (2015) Multi-omics profiling reveals that eating difficulties developed consecutively to artificial nutrition in the neonatal period are associated to specific saliva composition. J Proteomics. 128:105-12. (IF :3.9)             
  • Bros P, Delatour V, Vialaret J, Lalere B, Barthelemy N, Gabelle A, Lehmann S, Hirtz C (2015). Quantitative detection of amyloid-β peptides by mass spectrometry: state of the art and clinical applications. Clin Chem Lab Med. 1;53(10):1483-93. (IF : 3)  
  • Lehmann S, Vialaret J, Gras Combe G, Bauchet L, Hanon O, Girard M, Gabelle A, Hirtz C (2015). Stable Isotope Labeling by Amino acid in Vivo (SILAV): a new method to explore protein metabolism. Rapid Commun Mass Spectrom. 30;29(20):1917-25. (IF:2.5)
  • D Renard, A Waconge, X Ayrignac, C Mahmoud, G Fourcade, S Azakri, A Le Floch, S Bouly, C Marelli, C Tosi, C Arquizan, C Hirtz, A Gabelle, E Thouvenot and S Lehmann (2015). Cerebropsinal fluid Alzheimer’s disease biomarkers in cerebral amyloid angiopathy-related inflammation. Journal of Alzheimer Disease. (IF:4.1) 50(3):759-64.
  • Lehmann S and Hirtz C (2015). What is the potential of dried matrix spot sampling for cerebrospinal fluid analysis? Bioanalysis. (IF :3.1) Nov;7(22):2849-51.
  • Bissonnette L, Antoine Y, Tiers L, Hirtz C, Lehmann S, Bissonnette F, Kadoch I.J, Haouzi D, Hamama S. (2015) S100A10 plays a crucial role in the acquisition of the human endometrial receptivity phenotype and implantation process. Journal of Cell Science (IF:4) Jan 13:0 3;10(3):282-98.
  • Barthélemy N, Fenaille F, Hirtz C, Sergeant N, Schraen-Maschke S, Vialaret J, Buée L, Gabelle A, Junot C, Lehmann S and Becher F (2015). Tau protein quantification in human cerebrospinal fluid by targeted mass spectrometry at high sequence coverage. J.Prot. Research. (IF: 5.46)           5;15(2):667-76.
  • Hirtz C, J Vialaret, G Nouadje, S  Schraen, P Benlian, S Mary, P Philibert, L Tiers, P Bros, C Delaby,  A Gabelle, S Lehmann (2015). Comparison of LC-MRM Mass Spectrometry and semi-automatic Isofocusing approaches for the determination of Apolipoprotein E serotyping. Clinica Chimica Acta. (IF:3) 15;454:33-8.
  • A Gabelle, S Lehmann (2015). Comparison of LC-MRM Mass Spectrometry and semi-automatic Isofocusing approaches for the determination of Apolipoprotein E serotyping. Clinica Chimica Acta. (IF:3) 15;454:33-8.
2014
  • Delaby C, Gabelle A, Meynier P, Loubiere V, Vialaret J, Tiers L, Ducos J, Hirtz C & Lehmann S (2014).  Development and validation of dried matrix spot sampling for the quantitative determination of amyloid beta peptides in cerebrospinal fluid. Clin Chem Lab Med. 23:1-7. (IF : 3)     
  • Lehmann S, Schraen S, Quadrio I, Paquet C, Bombois S, Delaby C, Dorey A, Dumurgier J, Hirtz C, Krolak-Salmon P, Laplanche JL, Moreaud O, Peoc’h K, Rouaud O, Sablonnière B, Thouvenot E, Touchon J, Vercruysse O, Hugon J, Gabelle A, Pasquier F, Perret-Liaudet A (2014). Impact of harmonization of collection tubes on Alzheimer’s disease diagnosis. Alzheimers Dement. S1552-5260(13)02495-3. (IF : 14.5)          
  • Delaby C, Vialaret J, Bros P, Gabelle A, Lefebvre T, Puy H, Hirtz C and Lehmann S (2014).  Clinical measurement of Hepcidin-25 in human serum: Is quantitative mass spectrometry up to the job? EuPA Open Proteomics. Volume 3, Pages 60-67. (IF : 4.1)           
  • Lehmann S, Vialaret J, Seveno M, Tiers L, Gabelle A and  Hirtz C (2014). Comparison of hydrophobic, lipophilic and immunodepletion pre-fractionation methods for label-free LC-MS/MS identification of biomarkers in human cerebrospinal fluid. Journal of Proteomics & Bioinformatics. http://dx.doi.org/10.4172/jpb.S5-003. (IF : 2.6)
  • Barthelemy N, Lehmann S, Hirtz C, Gabelle A, Sergeant N, Fenaille F, Vialaret J, Schraen S, Bros P, Tiers L, Delaby C, Junot C, Touchon J, Buee L, Becher F. (2014) Detection and Quantification of the Tau Protein and Its Isoforms in the CSF of Alzheimer’s Disease Patients Using Mass Spectrometry. Alzheimer’s & Dementia.. 10 (no. 4 sup): p. 147. (IF : 14.5)         
2013
  • Lehmann S, Hoofnagle A, Hochstrasser D, Brede C, Glueckmann M, Cocho JA, Ceglarek U, Lenz C, Vialaret J, Scherl A, Hirtz C (2013). Quantitative Clinical Chemistry Proteomics (qCCP) using mass spectrometry: general characteristics and application. Clin Chem Lab Med. Nov 23:1-16. (IF : 3)         
  • Lehmann S, Delaby C, Vialaret J, Ducos J, Hirtz C (2013). Current and future use of “dried blood spot” analyses in clinical chemistry. Clin Chem Lab Med. 1:1-13. (IF : 3)        
  • Lehmann S, Delaby C, Touchon J, Hirtz C and Gabelle A (2013).  Biomarkers of Alzheimer’s disease: the present and the future. Rev. Neurol. (2013); 1 6 9. 7 1 9 – 7 2 3. (IF : 0.6)    
2011
  • Lehmann S, Poinot P, Tiers L, Junot C, Becher F, Hirtz C. (2011) From “Clinical Proteomics” to “Clinical Chemistry Proteomics”: considerations using quantitative mass-spectrometry as a model approach. Clin Chem Lab Med. Oct 8;50(2):235-42. (IF : 3)

Plateforme de Protéomique Clinique

Institute for Regenerative Medicine & Biotherapy (IRMB)
Hôpital Saint Eloi
80 rue Augustin Fliche
34295 MONTPELLIER – Cedex 5
FRANCE

Plan d’accès

Contact

Téléphone : 04 67 33 04 20 

Email